| Experiment ID | EXP00217 |
| Reference | Title: Identification of miR-187 and miR-182 as biomarkers of early diagnosis andprognosis in patients with prostate cancer treated with radical prostatectomy. Author: Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, MasiáE, Casanova J, Fernández-Serra A, Rubio L, Ramírez-Backhaus M,Armiñán A, Domínguez-Escrig J, Martínez F, García-Casado Z, ScotlandiK, Vicent MJ, López-Guerrero JA. Journal: J Urol. 2014 Jul;192(1):252-9. doi: 10.1016/j.juro.2014.01.107. Epub 2014 Feb 8. Abstract: PURPOSE: miRNAs are noncoding RNAs that negatively regulate target mRNA geneexpression. Aberrant miRNA expression is associated with prostate cancerpathogenesis. We identified miRNAs as potential biomarkers for prostate cancerdiagnosis and prognosis.MATERIALS AND METHODS: Total RNA was obtained from 10 normal prostate and 50prostate cancer samples, and analyzed using the GeneChip® miRNA 2.0 Array. At amedian followup of 92 months (range 2 to 189) an independent cohort of 273paraffin embedded prostate cancer samples was used for validation by quantitativereverse transcriptase-polymerase chain reaction. Another 92 urine samples frompatients undergoing prostate biopsy were evaluated for these miRNAs.RESULTS: miR-182 and 187, the miRNAs most differentially expressed between normaland tumor tissue, were selected for further validation. miR-187 inverselycorrelated with cT (p = 0.125) and pT (p = 0.0002) stages, Gleason score (p =0.003) and TMPRSS2-ERG status (p = 0.003). The log rank test showed associations of miR-182 with biochemical (p = 0.026) and clinical (p = 0.043) progression-freesurvival, as also noted on multivariate analysis. A significant independentimprovement in the definition of risk of progression was achieved by combiningmiR-182 expression with Gleason score (p <0.0001). miR-187 detection in urineprovided an independent predictive value for positive biopsy. A prediction model including serum prostate specific antigen, urine PCA3 and miR-187 provided 88.6% sensitivity and 50% specificity (AUC 0.711, p = 0.001).CONCLUSIONS: Results show that miR-182 and 187 are promising biomarkers forprostate cancer prognosis to identify patients at risk for progression and fordiagnosis to improve the predictive capability of existing biomarkers. PMID: 24518785 |
| Expressiion Profile | Description: Identification of miRNAs specific for prostate cancer (PCa) Organism: Homo sapiens GEO ID: GSE45604 Platform: GPL14613 Number of samples: 60 |
| Design and Sample | Cancer Type: prostate cancer Cancer SubType: N/D Cell Line: N/D Experimental Design: cancer vs normal Case Sample: prostate cancer Control Sample: normal prostate Num of Case: 50 Num of Control: 10 Quantification Software: Limma Num of miRNAs: 1105 |
| Identification | Num of Up: 20 Num of Down: 45 |